Constitutively Active RIP Kinases/Caspases
The disclosed technology offers recombinant programmed cell death enzymes that can constitutively trigger apoptosis, pyroptosis or necroptosis. These novel proteins have the potential to cause rapid cell death in diseased cells and are available for immediate generation of IND-enabling data.
High-Throughput Drug Screening of Cancer Stem Cells
This invention discloses methods for designing a personalized therapeutic regimen for patients with AML based on an individual's unique drug sensitivities. The methods offer clinical utility beyond the scope of standard diagnostics and assays and allow clinicians to tailor treatments based on a patient’s cancer stem cell chemosensitivity.
High-Throughput Drug Screens on a 3D Tumor-on-a-Chip to Monitor Cancer Cell Viability and Migration
The solution is a three-dimensional human renal cell carcinoma (RCC)-on-a-chip for screening drugs that could be developed as anti-metastasis agents.
Metabolite Biomarkers for the Detection of Colorectal Cancer
The technologies offer a simple yet powerful method for identifying serum markers of disease in colon cancer from peripheral blood. These technologies offer high sensitivity and specificity as compared to standard diagnostic methods such as colonoscopy but offer additional utility as they require no in-office clinical procedure. Together, they offer a promising new diagnostic and monitoring tool to support clinical decision making in colon cancer.
Minibinder-Drug Conjugates Targeting Human EpCAM and PDL1 Receptors for Targeted Cancer Therapy
This technology offers a set of novel polypeptides designed to bind to human EpCAM and PDL1 receptors, offering potential applications in treating cancer, autoimmune diseases, and inflammation.